IRLAF.US IRLAB Therapeutics AB (publ)

Healthcare Biotechnology USA Stocks
0.0800 USD
Close of Nov 15, 2026
0.0800 0.1000
Market cap
USD 11.9M
P/E
-
P/B
1.22x
ROE
-20.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is IRLAF.US undervalued?

Graham number

The Graham number of IRLAB Therapeutics AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IRLAB Therapeutics AB (publ) fundamental analysis

No fundamental analysis for IRLAB Therapeutics AB (publ) yet.

IRLAB Therapeutics AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IRLAB Therapeutics AB (publ)

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of fa…

Full company profile